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Chronic graft-versus-host disease (cGvHD) is a severe complication of allogeneic
hematopoietic stem cell transplantation that affects various organs leading to a reduced
quality of life. The condition often requires enduring immunosuppressive therapy, which
can also lead to the development of severe side effects. Several approaches including
small molecule inhibitors, antibodies, cytokines, and cellular therapies are now being
developed for the treatment of cGvHD, and some of these therapies have been or are
currently tested in clinical trials. In this review, we discuss these emerging therapies with
particular emphasis on tyrosine kinase inhibitors (TKIs). TKIs are a class of compounds
that inhibits tyrosine kinases, thereby preventing the dissemination of growth signals and
activation of key cellular proteins that are involved in cell growth and division. Because they
have been shown to inhibit key kinases in both B cells and T cells that are involved in the
pathophysiology of cGvHD, TKIs present new promising therapeutic approaches.
Ibrutinib, a Bruton tyrosine kinase (Btk) inhibitor, has recently been approved by the
Food and Drug Administration (FDA) in the United States for the treatment of adult patients
with cGvHD after failure of first-line of systemic therapy. Also, Janus Associated Kinases
(JAK1 and JAK2) inhibitors, such as itacitinib (JAK1) and ruxolitinib (JAK1 and 2), are
promising in the treatment of cGvHD. Herein, we present the current status and future
directions of the use of these new drugs with particular spotlight on their targeting of
specific intracellular signal transduction cascades important for cGvHD, in order to shed
some light on their possible mode of actions.
Keywords: chronic graft-versus-host disease, tyrosine kinase inhibitors, immunotherapy, Janus kinase 1/2,
hematopoietic stem cell transplantationorg October 2020 | Volume 11 | Article 5783141
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GvHD is a complication that often occurs after allogeneic
hematopoietic stem cell transplantation (allo-HSCT) in up to
50% of cases, where donor T- and B cells derived from the graft
recognize and attack host antigens (1). This is particularly
important because HSCT is the treatment of choice for many
types of malignant and non-malignant hematological and
autoimmune diseases. According to the onset, GvHD can be
acute (aGvHD) or chronic (cGvHD): aGvHD typically occurs in
less than 100 days after transplantation and it is associated
with inflammation in several organs or sites, such as skin,
gastrointestinal tract, mouth, genital tract or liver, while
cGvHD may present at any time after HSCT, even if it
typically occurs after 100 days from graft infusion (2).
Thus, from the clinical point of view, cGvHD resembles an
“autoimmune syndrome”, characterized by immune dysregulation
and absence of functional tolerance. As in systemic rheumatologic
diseases, its clinical manifestations are variable, varying from lichen
planus-like lesions to full sclerosis, muscle pain or joint fasciitis,
vulvo-vaginitis, bronchiolitis obliterans (BO), in addition to damage
of gastrointestinal tract and liver (3).Frontiers in Immunology | www.frontiersin.org 2The National Institute of Health (NIH) consensus established
diagnostic criteria for cGvHD in 2005 (4), which were revised
in 2014 (5). The authors defined cGvHD-specific organ
manifestations and elaborated a scoring system by considering
the severity of involvement of skin, mouth, eyes, gastrointestinal
tract, liver, lungs, joint fascia, and genital tract differently from
other hematological diseases, and from models for testing
conditioning or immunosuppressive regimens. Unfortunately,
the existing murine models of cGvHD fail to fully include the
whole spectrum of human cGvHD symptoms, which makes it
difficult to treat and to draw general conclusions about the
efficacy of new therapeutic approaches based on animal
models (6).
In the pathogenesis of cGvHD, the disease develops as a result
of complex molecular networks, from thymus damage to unusual
antigen presentation and aberrant T- and B cell interactions
(Figures 1A, B). This consequently leads to an enhanced Th17
differentiation, macrophage sequestration in tissues, alloantibody
formation, and fibrosis, with the latter highly dependent on
nuclear factor kappa-light-chain-enhancer of activated B cells
(NF-kB) activation and inflammatory cytokines production (7).
Usually, the initial phase starts with release of inflammatoryA B
C
FIGURE 1 | Chronic GvHD development and novel agents targeting B and T cells that are under investigation for the treatment of the disease. Following bone
marrow transplantation, healthy production of effector B and T cells from the bone marrow may trigger a normal healthy immune response leading to a healthy
immune homeostasis (A). Overproduction of self-reactive B and T cells from donor-derived bone marrow grafts may cause immune dysregulation, which on the one
hand may lead to the destruction of healthy tissues, activate and recruit macrophages important for the production of collagen within tissues, thereby, causing
fibrosis and scleroderma and subsequently, development of cGvHD. On the other hand, production of self-reactive antibody complexes may be triggered by self-
reactive B cells from donor-derived bone marrow grafts, which may be deposited into healthy tissues and blood vessels and subsequently leading to the
development of cGvHD (B). Novel agents targeting either B- or T cells that are under investigation for the treatment of cGvHD (C). TCR, T cell receptor; TKIs,
tyrosine kinase inhibitors; IL-2R, interleukin-2 receptor; ITK, IL-2–inducible kinase; JAK1/2, Janus kinase 1/2; mTOR, mammalian target of rapamycin; HDAC, histone
deacetylase; AP-1, activator protein 1; Sirt1, sirtuin 1; Tregs, regulatory T cells; Ab, antibody; Th1, Type 1 T-helper; ROCK2, Rho-associated coiled-coil kinase 2;
BLNK, B cell linker; NF-kB, nuclear factor kappa-light-chain-enhancer of activated B cells; NFAT, nuclear factor of activated T cells; ITAMS, immunereceptor
tyrosine-based activation motifs; CSF-1R, colony-stimulating factor 1 receptor; BCR, B cell receptor; Btk, Bruton tyrosine kinase; Syk, splenic tyrosine kinase; BAFF,
B cell activating factor; BAFF-R, BAFF receptor; ERK, extracellular signal-regulated kinase; CD20, cluster of differentiation 20; CD40L, cluster of differentiation 40
ligand; Ag, antigen; IL-6R, interleukin-6 receptor.October 2020 | Volume 11 | Article 578314
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conditioning regimens. These cytokines [interleukin-1 (IL-1),
tumor necrosis factor alpha (TNF-a), interferon gamma (IFN-g),
platelet-derived growth factor (PDGF)] in combination with
antigen presenting cells, stimulate the activation of donor allo-
reactive T cells, with expansion of donor helper T cells, cytotoxic
T cells and natural killer (NK) cells that cause cytotoxicity
against host cells. In addition, both colony-stimulating factor-1
(CSF-1) and granulocyte macrophage-colony stimulating factor
(GM-CSF), two key cytokines that modulate the differentiation,
proliferation and survival of macrophages, have been implicated
in cGvHD (8, 9). The role of GM-CSF activated myeloid cells in
mediating GvHD by favoring IL-1b and Reactive Oxygen Species
(ROS) production by phagocytes has recently been highlighted
(10). This tissue damage is not counterbalanced by the
physiologic control exerted by the host thymus and of T
regulatory lymphocytes (Tregs) that usually are fundamental
for immune tolerance (11). Donor macrophages may also
infiltrate organs like the skin and lungs of a HSCT recipient
through CSF-1 receptor signaling; and studies have shown that
these donor CSF-1R-dependent macrophages may contribute to
both sclerodermatous (Scl)-cGvHD and lung cGvHD, otherwise
known as bronchiolitis obliterans syndrome (BOS), via the
expression of Transforming Growth Factor beta (TGF-b) (8).
This is important because it is now well established that TGF-b is
a fundamental pathogenic cytokine in fibrosis, and elevated
levels of this cytokine has been found in cGvHD patients;
though the mechanism through which it contributes to the
pathogenesis of the disease remains elusive (3). It is, however,
clear that in certain organ-specific cGvHDs, such as skin cGvHD,
both the TGF-b and PDGF pathways appear to be up-regulated
leading to the activation and differentiation of fibroblasts into
alpha-smooth muscle actin (a-SMA)-expressing myofibroblasts.
These a-SMA-expressing myofibroblasts then proliferate and
mediate fibrosis in Scl-cGvHD (12, 13).
Fibroblasts are also fundamental in the pathogenesis of
cGvHD involving lacrimal glands, in a different way in respect
of Sjogren syndrome. Indeed, fibroblasts act as antigen
presenting cells and communicate with various inflammatory
cells leading to the invasion of ductal epithelium with its
destruction and ductal ectasia of lacrimal glands (14). The
involvement of the eyes is so clinically relevant because
worsening of cGvHD score in the eyes, joints/fascia, or oral
mucosa, when assessed at 6 months, are more likely to predict
subsequent treatment failure; with 74% patients free from failure
at 36 months when no impairment of symptoms and signs were
observed at 6 months vs 26% of those that presented a higher eye,
mouth or joints involvement and inflammation (15).
The “hyperinflammatory” status that characterizes cGvHD
has been known for many years; in 2012, a group from Bethesda
elaborated on a simple but effective score for predicting the
severity of cGvHD using some parameters typical of
autoimmune diseases, such as C reactive protein (CRP),
complement (C3 and C4), platelets and albumin levels. When
CRP is >0.7 mg/dl, C3 >140 mg/dl, C4 >28 mg/dl, platelets >250
K/ml and albumin <3.6 g/dl were all present, the chances of activeFrontiers in Immunology | www.frontiersin.org 3cGvHD was 80% vs 69% when 1–3 parameters were present and
0% when all variables were lower than the cut off (16).
Moreover, an interestingassociationbetween the “inflammatory
phenotype” of patients with cGvHD and microbiome composition
is emerging. Indeed, gut microbiota of healthy patients has been
compared with subjects who underwent allo-HSCT but did not
develop cGvHD. The first cohort was enriched with Bacteroides,
Lactobacillus, Clostridium, and Veillonella, whereas, in the group
without cGvHD, two were enriched with Ruminococcus, Blautia,
andFaecalibacterium. The latter is awell-knownanti-inflammatory
commensal bacterium, which was previously reported in patients
with intestinal inflammatory diseases including active ulcerative
colitis, and its presence correlated with higher amounts of IL-
10 (17).
This is the prerequisite for employing anti-inflammatory
agents (such as Btk inhibitors, JAK1/2 inhibitors or
hydroxychloroquine) in the therapy of cGvHD as described below.
The psychological and economic impact of cGvHD is still
enormous, as many complications can emerge from both the
disease and its treatment (18). Chronic GvHD impairs the
quality of life of the affected patients who require a continued
medical follow-up, with higher risk of infection and death. Even
the administration of corticosteroids is problematic: in a cohort
of 162 patients, it was clearly demonstrated, that cGvHD and
steroid treatment significantly prolonged time to recover normal
body mass index (BMI) and muscle strength after HSCT (19).
Acute GvHD occurs in 40%–50% of patients receiving allo-
HSCT, which makes aGvHD a major risk factor for developing
cGvHD (20). Other known risk factors include specific diseases,
such as chronic myeloid leukemia (CML), age (older patients are
more prone to cGvHD), use of mismatched or unrelated donors
compared to matched sibling transplants, use of peripheral blood
stem cells instead of bone marrow stem cells as a graft source,
and sex mismatch between recipients (especially male) and
donor (especially female) (21, 22). This review therefore,
provides the current knowledge on the emerging therapies for
cGvHD, with particular emphasis on TKIs, JAK1/JAK2, and
proteasome inhibitors that are now ready for entering into
clinical practice.TREATMENT OF CHRONIC GRAFT-
VERSUS-HOST DISEASE
Standard of care in the treatment of cGvHD depends on the
particular organ(s) or site(s) that is/are affected and adopted
treatments can be topical or systemic. Nevertheless, about 50%–
60% of patients with cGvHD will require a second-line treatment
within 2 years, but at the moment there is no consensus on the
optimal choice of agents for second or further lines of therapy
(23). The National Comprehensive Cancer Network (NCCN)
guidelines (https://www.nccn.org/professionals/physician_gls/
pdf/hct.pdf) and the European Society for Blood and Marrow
Transplantation (EBMT) consensus (24), both edited in 2020,
agree in the use of steroids as first-line treatment, and sustain the
use of ibrutinib, the only compound approved by the FDA forOctober 2020 | Volume 11 | Article 578314
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guidelines clearly state that there are still no standard therapies
for steroid-resistant (SR) patients, limiting the patients to the
listed available drugs (see Table 1), and advising clinicians to
possibly enroll these patients into clinical trials.
It also must be noted that cGvHD severely impairs the quality
of life. Hence, it is imperative that new treatment options be firstly
aimed at improving the quality of life by reducing symptoms,
preventing immune-mediated damage and disability, while at the
same time avoiding toxicities that are associated to the treatment
itself (25, 26). The long-term goal of cGvHD treatment on the
other hand, is to institute an immunologic tolerance that will allow
the patient to successfully withdraw from immunosuppressive
treatments without relapse or clinically significant manifestations
of disease activity while preserving the graft-versus-leukemia
(GVL) effect (25, 26).
The current available treatment options for cGvHD firstly
involve the use of corticosteroids. Due to their lymphopenic and
anti-inflammatory properties, and generally based on controlled
clinical trials, corticosteroids (such as prednisone) have been the
mainstay of first-line treatment of cGvHD for the past three
decades (27, 28). These corticosteroids can be administered alone
or in combination with other immuno-suppressants such as
calcineurin inhibitors, which suppress the immune system by
preventing the production of IL-2 by T cells (26–29). This
treatment option is sometimes however problematic as it is
often inadequate or toxic, and can cause immunosuppression
that may lead to an increase in malignancy relapse. Side effects,
such as infections, myopathy, cataracts, hyperglycemia, decline
in bone mass, and avascular necrosis have all been associated
with prolonged corticosteroid use. Combination therapy with
immuno-suppressants to reduce these side effects has shown
little or no benefit (27, 28). Furthermore, deteriorating signs of
cGvHD in previously affected organs along with the developmentFrontiers in Immunology | www.frontiersin.org 4of signs and symptoms of the disease in previously unaffected
organs have both also been associated to corticosteroid treatment
(26); all of which warrants a second line of treatment in nearly
50%–60% of patients who experience reoccurrence of cGvHD
(16). Second-line cGvHD treatment is based on retrospective
analyses, and in some cases, single-arm phase II trials (23).
Whatever line of therapy, the treatment of cGvHD has three
different goals:
i. to reduce the activated status of B- and T cells: in this
context, Btk inhibitors can reduce the pre-germinal B cells and
T follicular helper (Tfh) lymphocytes; JAK1/2 inhibitors can
decrease Th1, Th2, and Th17 activity, and anti-B and anti-T
cells monoclonal antibodies (mAbs) seem to be also effective.
Among the latter drugs, anti-CD20 and anti-CD52 antibodies
have already entered into the clinical practice and the anti-
CD26 mAb Begelomab seems to be very promising (30).
ii. to play an anti-inflammatory effect, in particular by reducing
secretion of IL-6, TNF-a and IL-17. In this category, the most
frequently adopted antibodies are Infliximab and Etanercept
along with the JAK1 inhibitor Itacitinib.
iii. to slow down the development of fibrosis: in addition to
macrophages and pathogenic TGF-b, recent studies have
also suggested that fibroblasts isolated from cGvHD patients
can promote fibrosis through the upregulation of collagen
genes (COL1a1 and COL1a2), a mechanisms which was
induced by hyperactive TGF-b signaling (31). In this context,
inhibitors of CSF-1, the TGF-b pathway, PDGF, spleen
tyrosine kinase (Syk), Rho-associated coiled-coil kinase 2
(ROCK2) and Hedgehog seem promising approaches [see in
the following references (3, 32, 33)].
Table 2 highlights some of the agents that are currently
being evaluated in patients with cGvHD. The use of some ofTABLE 1 | Possible therapeutic approaches for steroid-resistant/refractory cGvHD patients according to the NCCN and EBMT 2020 guidelines (24).
Drug Response
(%)
Target sites Adverse events Notes
Ibrutinib ORR 69 skin, mouth, GI bleeding, diarrhea, fatigue, pneumonia, nausea, hematological tox,
spasms
approved by FDA
advised also by
EBMT
Extracorporeal photopheresis
(ECP)
ORR 53–61 skin, liver, eyes, mucosa EBMT advised
Calcineurin inhibitors ORR 35–46 skin, liver, GI kidney, hypomagnesaemia, hypertension, tremors EBMT advised
Mycophenolate mophetyl ORR 75 skin, mouth abdominal cramps, infections EBMT advised
JAK1/2 inhibitors ORR 43–85 skin, mouth, lung, joints cytopenias, CMV reactivation EBMT advised
Low-dose methotrexate ORR 70 skin, mouth cytopenias Expert opinion
Rituximab ORR 66 skin, mouth, liver, lungs infusion reactions, infections EBMT advised
Alemtuzumab ORR 40–70 skin infections Expert opinion
mTOR inhibitors ORR 63–81 skin, mouth, liver, eyes, GI thrombotic microangiopathy EBMT advised
IL-2 ORR 50–60 skin, liver, GI, lung, joints flu-like syndrome Expert opinion
TKIs ORR 36 skin, GI, lung edema, fatigue, ipophosphatemia EBMT advised
Etanercept ORR 62 lung infections Expert opinion
Abatacept ORR 44 mouth, GI, joints, skin, eyes,
lung
infections, diarrhea, fatigue Expert opinion
Hydroxychloroquine ORR 53 skin, mouth, liver retinopathy Expert opinion
Pentostatin ORR 55 skin, mouth, muscles, GI renal, fatigue, nausea, infections EBMT advisedOctober 2020 | VolumeEBMT, European Society for Blood and Marrow Transplantation; NCCN, National Comprehensive Cancer Network; ORR, overall response rate; IL-2, interleukin-2; JAK, Janus associated
kinases; GI, gastro-intestinal; TKIs, tyrosine kinase inhibitors; CMV, cytomegalovirus; mTOR, mammalian target of rapamycin.11 | Article 578314
Saidu et al. Treating Chronic Graft-Versus-Host Diseasethese agents to treat cGvHD is based on their current usage in
the clinic to treat certain autoimmune diseases, where their
tolerability and efficacy profiles are known. In addition,
patients with cGvHD often display symptoms resemblingFrontiers in Immunology | www.frontiersin.org 5autoimmune diseases, making these agents appealing
for cGvHD treatment. The mechanism of action of these
agents on both B and T cells in cGvHD is illustrated in
Figure 1C.TABLE 2 | Selected ongoing studies evaluating novel drug agents in patients with cGvHD.
Agent Agent type Target ClinicalTrial.gov
identifier
Clinical
trials
(status)
Clinical trials (status)
Imatinib TKI BCR-ABL, inhibits B cell signaling NCT01309997 II Imatinib treating cutaneous sclerosis in
patients with cGvHD
Nilotinib TKI BCR-ABL, inhibits B cell signaling NCT01810718 I/II Nilotinib for treating patients with steroid-
refractory cGvHD
Ibrutinib TKI Btk, Syk, Itk NCT03790332 I/II Dose/safety study of ibrutinib in pediatric
patients with cGvHD
Fostamatinib TKI Syk, inhibits B cell signaling NCT02611063 I Fostamatinib - preventing and treating
cGvHD after allogeneic stem cell transplant
Entospletinib
(ENTO)
TKI Syk, inhibits B cell signaling NCT02701634 II Entospletinib + systemic corticosteroids as
first-line therapy for cGvHD
Itacitinib TKI JAK1 NCT03584516 III Itacitinib + corticosteroids as initial
treatment for cGvHD
Ruxolitinib TKI JAK1/2 NCT03395340 II Topical ruxolitinib for cGvHD
Ruxolitinib TKI JAK1/2 NCT03616184 II Ruxolitinib for sclerotic cGvHD after failure
of systemic steroid therapy
Baricitinib TKI JAK1/2 NCT02759731 I/II JAK1/2 Inhibition in cGvHD
Vismodegib TKI Hedgehog, inhibits SMO NCT02337517 N/A Vismodegib for treating patients with
steroid-refractory cGvHD
Sonidegib
(LDE225)
TKI Hedgehog, inhibits SMO NCT02086513 I Sonidegib for treating SR-cGvHD after
allo-HSCT
Ixazomib Proteasome inhibitor 26S Proteasome NCT03225417 I/II Ixazomib + rapamycin and tacrolimus in
the prophylaxis of cGvHD
Bortezomib
(Velcade)
Proteasome inhibitor Suppresses T cell, proliferation and growth and
inhibits B cell activation via NF-kB inhibition
NCT00815919 II Bortezomib + Prednisone as initial
treatment for cGvHD
Carfilzomib Proteasome inhibitor Suppresses T cell, and B cell development,
activation and survival
NCT02491359 II Carfilzomib therapy for cGvHD
KD025 ROCK2 inhibitor ROCK2, pSTAT3, IL-17 and IL-21 inhibition NCT03640481 II ROCK2 inhibition in cGvHD after at least
two prior lines of systemic therapy
KD025 ROCK2 inhibitor ROCK2, pSTAT3, IL-17 and IL-21 inhibition NCT02841995 II To evaluate, safety, tolerability and activity
of KD025 in patients with cGvHD
Panobinostat
(LBH589)
Deacetylase inhibitor Inhibits HDAC NCT01028313 II LBH589 as second-line therapy for
patients with cGvHD
Rituximab Monoclonal antibody Anti-CD20, depletes B cells NCT01161628 II Safety/efficacy of rituximab as primary
treatment for extensive cGvHD
Ofatumumab Monoclonal antibody Anti-CD20, depletes B cells NCT01680965 I/II Safety/side effects of ofatumumab in
cGvHD
Axatilimab
(SNDX-6352)
Monoclonal antibody Blocks CSF-1R NCT03604692 I Investigate SNDX-6352 in subjects with
active cGvHD
Abatacept Fusion protein Inhibits the CD28 signaling pathway of T cell. NCT01954979 I Abatacept for treating patients with
steroid-refractory cGvHD
Alefacept Fusion protein Inhibits T cell activation and proliferation NCT01226420 II Alefacept for steroid-refractory cGvHD
IL-2 Cytokine Tregs development and expansion NCT01366092 II Low-dose IL-2 for steroid-refractory
cGvHD
ECP +
Aldesleukin
(Proleukin)
ECP + Cytokine Expands Tregs, NK-cells NCT03007238 II ECP + low dose IL-2 (interleukin 2)
(aldesleukin)
AMG 592 IL-2 mutein Expands Tregs, NK-cells NCT03422627 I Safety/efficacy of AMG 592 in patients with
steroid-refractory in cGvHD
Ibrutinib +
Rituximab
TKI + Monoclonal
antibody
Btk, Syk, Itk, Anti-CD20, depletes B cells NCT03689894 I Combining ibrutinib and rituximab for the
treatment of cGvHD
PredEver Immunosuppressant
+ mTOR inhibitor
Glucocorticoid receptors, inhibit IL-2 mediated
activation of B and T cells
NCT01862965 II Prednisone + Everolimus for treating
patients with moderate to severe cGvHDO
TKI, tyrosine kinase inhibitor; aGvHD, acute graft versus host disease; cGvHD, chronic GvHD; Btk, Bruton tyrosine kinase; Itk, Interleukin-2-inducible kinase; Syk, spleen tyrosine kinase;
JAK, Janus associated kinases; BCR-ABL1, breakpoint cluster region-Abelson; CSF-1R, colony-stimulating factor 1 receptor; ROCK2, Rho-associated coiled-coil kinase 2; IL-2,
interleukin-2; pSTAT3, phosphorylated-signal transducer and activator of transcription 3; mTOR, mammalian target of rapamycin; CD20, cluster of differentiation 20; NF-kB, nuclear factor
kappa-light-chain-enhancer of activated B cells; NK, natural killer; Tregs, regulatory T cells; HDAC, histone deacetylase; ECP, extracorporeal photopheresis; HSCT, hematopoietic stem
cell transplantation; SMO, smoothened; N/A, not applicable.ctober 2020 | Volume 11 | Article 578314
Saidu et al. Treating Chronic Graft-Versus-Host DiseaseRATIONALE FOR TARGETING B CELLS
It is now quite clear that in addition to alloreactive T cells, allo-
and auto-reactive B cells along with several cytokines, play a
fundamental role in the development of cGvHD (1, 3, 34–39).
Undoubtedly, a central event in the pathogenesis of cGvHD is
the recognition of antigen (Ag) via the B cell receptor (BCR). A
major difference to the physiological recognition of antigen by
the BCR has been demonstrated in the murine model, where B
cells have a BCR-hyper-responsiveness in mice developing
cGvHD (36–39). When pathogenic B cells are activated in
cGvHD, they expand in a process that is guided by soluble
factors, including IL-4, IL-17, IL-21, and B cell activating factor
(BAFF), which is connected to the formation of germinal centers
(GCs) (37, 40, 41). Donor Tfh cells cooperate with GC B cells
that undergo somatic hypermutation by amassing B cells capable
of producing antibodies to antigens, thereby, activating the BCR
and thus, supporting cGvHD [as reviewed in (36)]. The increased
number of circulating Tfh cells may thus serve as a surrogate
marker of the presence of these Tfh cells in GCs: in a cohort of 70
patients, the number of circulating Tfh cells increased in patients
with cGvHD, especially in those with higher severity of disease,
where the expansion of Tfh was highly correlated with the
generation of IgG1 antibodies (36).
Furthermore, clinical studies have demonstrated a striking
increase of BAFF in the plasma of patients with cGvHD, and also
of the BCR intercellular signaling molecules, such as Syk and B cell
linker (BLNK) (42), which are relevant for cGvHD development. In
preclinical studies, mice lacking Btk failed to develop cGvHD (39).
It must be noted that when Syk is phosphorylated upon BCR
engagement, it sustains B cell survival and proliferation, and
promotes monocyte migration and fibrosis in cGvHD murine
models (43). Moreover, after linking to its receptor, BAFF also
activates extracellular regulated kinase (ERK), Protein kinase B
(Akt), and NF-kB; hence, proteasome inhibitors, such as
bortezomib and ixazomib, which are able to block the NF-kB
signaling, can be good candidates for the treatment for cGvHD (6).RATIONALE FOR TARGETING T CELLS
Chronic GvHD, as mentioned earlier, is an immunologic attack of
host organs or tissues by donor T cells and B cells following HSCT.
Donor T-helper (Th) cells are crucial in GvHD initiation, owing to
their ability to differentiate into Th1 (secreting IL-2 and IFN-g), Th2
(secreting IL-4, IL-5, IL-10 and IL-13), Th17 (secreting IL-17), and
Tfh cells, which facilitate organ-specific GvHD (44). Previously
published studies have shown that cGvHD results from the selective
activation of allo-reactive donor CD4+ T cells that act as helpers to
host B cells, thereby triggering B cell activation and auto-antibody
production (45). In addition, CD4+ Foxp3+ regulatory T cells are
important mediators of immune tolerance, and their impairment
has been associated with cGvHD (46).
Some of the new therapeutic approaches for cGvHD are
therefore aimed at targeting T cell responses or T cell signaling
pathways. For example, the critical homeostatic cytokine IL-2, at
low doses, can be used to target Treg development and expansionFrontiers in Immunology | www.frontiersin.org 6as shown in a phase I clinical trial, where 1.5 × 106 IU/m2/day of
IL-2 was able to selectively target and enhance Tregs, with
improvement of patients with cGvHD (47). Aldesleukin, a
recombinant human IL-2, in combination with extracorporeal
photopheresis (ECP) to treat SR-cGvHD, is also in a phase II
clinical trial. Furthermore, the safety and tolerability of AMG
592, an IL-2 mutein, is been evaluated in a phase I/II clinical trial
in subjects with SR-cGvHD (ClinicalTrials.gov identifier:
NCT03007238, NCT03422627).
At the ASH meeting held in 2018, it was reported that
artesunate (a drug used for treating malaria) improved the
survival of mice with cGvHD by increasing the number of
Tregs and decreasing that of Th17 both in peripheral blood
(PB) and spleen, further sustaining the role of T cells in
mediating cGvHD (48).
Other agents targeting T cells include abatacept and alefacept
(both of which target and inhibits the activation and
proliferation of T cells), the ROCK2 inhibitor KD025 (49), and
the proteasome inhibitors ixazomib (50), bortezomib (51),
carfilzomib (52), and ibrutinib (53). These agents are discussed
in a more detail later in this review.THE ROLE OF SYK, BTK, AND ITK IN THE
DEVELOPMENT OF CGVHD
Syk, Btk and IL-2-inducible T cell kinase (Itk) are cytoplasmic
TKs that are fundamental for the development of B- and T cells,
playing multiple functions in the immune system. In general, Btk
and Syk are crucial for the phosphorylation and activation of
downstream effectors in BCR signaling, while Itk is crucial for the
activation of downstream effectors in TCR signaling. Moreover,
Syk is involved in immune receptor signaling, such as BCR
signaling that promotes B cell proliferation and survival, but also
in control of cell migration, cellular adhesion, innate immune
recognition, platelet activation and vascular development, while
Btk is responsible for B cell development, differentiation and
signaling (54). Moreover, Btk is central in control of the Toll-like
receptor (TLR)-induced IL-10 expression by B cells, and is an
active part of the NLRP3 inflammasome, a multimeric protein
complex that triggers the release of proinflammatory cytokines,
such as IL-1b and IL-18, in many inflammatory conditions,
including Alzheimer’s disease, diabetes, and infections (55), and
lack of Btk can lead to a compromised BCR-induced
proliferation and survival. Finally, Itk is responsible for T cell
development, differentiation and signaling (56).
Recent studies demonstrated that Btk, Itk, and Syk, may all be
required for the development of cGvHD (39, 43, 57). It is worth
noting that upon engagement of the BCR and TCR with a
signaling molecule, SRC family kinases, including Lck/Yes
novel tyrosine kinase (Lyn) and lymphocyte-specific protein
tyrosine kinase (Lck), are activated leading to the subsequent
activation of Syk, Btk and Itk. These activated molecules then
activate some transcription factors such as NF-kB in B cells and
nuclear factor of activated T cells (NF-AT) in T cells,
subsequently controlling cell survival, proliferation, andOctober 2020 | Volume 11 | Article 578314
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1B). This is important in the pathophysiology of cGvHD as Btk
activation can drive the production of self-reactive antibody
complexes which may be deposited within healthy tissues and
blood vessels and hence, promote cGvHD development (Figure
1A). Furthermore, pro-inflammatory cytokines produced as a
result of Syk, Btk, or Itk signaling can have a direct effect on
cGvHD target tissues (58, 59).EMERGING THERAPIES FOR CHRONIC
GRAFT-VERSUS-HOST DISEASE
Several agents are currently under investigation for the treatment
of cGvHD, which act by either targeting B cells or T cells, or both,
and/or macrophages. These agents include TKIs, anti-CD20
monoclonal antibodies and Syk inhibitors, which target B cells,
proteasome inhibitors, which target T cells, and JAK1/2 and Btk
inhibitors, which target both B and T cells (24). Some of these
agents are discussed below according to their known
mechanisms of action.
Inhibition of Tyrosine Kinases
Tyrosine kinases (TKs) have been implicated in several cellular
processes including differentiation, proliferation, anti-apoptosis,Frontiers in Immunology | www.frontiersin.org 7and B and T cell signaling (28, 53, 60–63). Consequently, the
tyrosine kinase inhibitors (TKIs), by blocking B and T cell
activation, could be appealing for the treatment of cGvHD.
TKIs function by binding to ATP-binding catalytic sites of the
tyrosine kinase domains on receptor (RTKs) and on non-receptor
TKs. In the absence of TK activity, substrates necessary for RTK
function cannot be phosphorylated and consequent cellular
events are abrogated. Hence, TKIs can cause a blockade of
downstream intracellular signaling and transcription of genes,
including some pro-inflammatory cytokines (Figure 2).
The efficacy profiles along with the mechanism of action of
most of these TKIs are also known, as they have long been used to
treat hematological diseases, such as acute leukemia (67), chronic
lymphocytic (CLL) (68). In CML, for example, the rearrangement
of BCR and ABL1 genes gives origin to a fusion gene where the
control of the ABL1 kinase function is lost and so the new protein
is constitutively active, with the consequent excess of proliferation
of myeloid precursors and an abnormal interaction of the
leukemic stem cells with the actin and the bone marrow stroma
(69) (Figure 2, left hand panel).
TKIs can also bind and occupy ATP- or substrate-binding
sites on transmembrane transporters, such as the ATP-binding
cassette (ABC) efflux pumps and the human organic cation
transport member 1 (hOTC1) influx protein (64–66) thereby
affecting drug and cellular responses (Figure 2, right handA B
FIGURE 2 | A generalized proposed mechanism of action of tyrosine kinase inhibitors (TKIs). (A) auto-phosphorylation of receptor TK (RTK) (light green) upon ligand
(brown) binding activates TKs (purple) downstream leading to transcriptional activation. RTK functions by binding ATP and transferring phosphate from ATP to
tyrosine residues on various substrates, which leads to their phosphorylation and subsequent cellular response; such as the excess proliferation of cells. Intracellular
non-RTKs can also bind ATP and transfer phosphate from ATP to tyrosine residues on various substrates, which can also lead to their phosphorylation and
subsequent cellular response. The plasma membrane also has influx and efflux transporters that are ATP-gated (left hand panel). (B) In the absence of TK activity,
substrates necessary for RTK function cannot be phosphorylated and consequent cellular events are abrogated. Hence, TKIs function by binding to ATP-binding
catalytic sites of the TK domains on RTKs or on non-RTKs, thereby, preventing TK phosphorylation and inhibiting down-stream intracellular signaling and
transcription of genes such as pro-inflammatory cytokines. TKIs can also bind and occupy ATP- or substrate-binding sites on transmembrane transporters such as
the hOTC1 influx protein and the ABC efflux pumps (64–66), thereby, affecting drug and cellular responses (right hand panel). RTK, receptor tyrosine kinase; TK,
tyrosine kinase; hOCT1, human organic cation transport member 1; ABC, ATP-binding cassette; ABCB1, ABC sub-family B member 1 (P-glycoprotein 1); ATP,
adenosine triphosphate; ADP, adenosine diphosphate; p, phosphate; NDB1, nucleotide binding domain 1; NDB2, nucleotide binding domain 2; TMD1,
transmembrane domain 1; TMD2, transmembrane domain 2; TKI, tyrosine kinase inhibitor.October 2020 | Volume 11 | Article 578314
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shown to not only target and inhibit BCR-ABL1, but also c-KIT,
PDGF receptor (PDGFR), and Src family kinases, which results
in the abrogation of the transcription of pro-inflammatory
cytokines such as IL-1, IL-6, and TNF-a, and prevents the
proliferation of myeloid cells (70).
In cGvHD, TKIs could be used to inhibit growth factor
receptor pathways such as those of PDGFR, epidermal growth
factor receptor (EGFR) and TGF-b pathways. Indeed, ABL1 is
located downstream of TGF-b, and in preclinical models of
systemic sclerosis, a disease which may resemble Scl-cGvHD,
the production of proteins of the extra-cellular matrix by TGF-b
was significantly decreased in ABL1-deficient cells (71). On the
other hand, it has been clearly demonstrated that many TKs,
such as PDGFR, vascular endothelial growth factor receptor
(VEGFR) and EGFR are significantly increased during liver
fibrosis development, transforming the hepatic stellate cells
from resting to active (63, 72). In addition, other signaling
pathways, such as MEK/ERK and phosphatidylinositol-3
kinase (PI3K)/Akt seem to be activated by TKs during hepatic
stellate cells activation; this is the basis for employing TKIs in
diseases such as liver fibrosis (72) Table 3.Frontiers in Immunology | www.frontiersin.org 8Imatinib is a first generation TKI approved for the treatment
of CML and Philadelphia-positive acute lymphoblastic leukemia
(ALL) and for myelodysplastic/myeloproliferative diseases
carrying the PDGFR rearrangement. In addition to the BCR-
ABL1 fusion protein, imatinib can also target and inhibit PDGFR
and TGF-b pathways both of which play important roles in the
fibrosing process occurring in Scl-cGvHD. Hence, targeting these
growth factors could represent an important therapeutic strategy
for treatment of cGvHD (90, 91).
In a murine model of bleomycin-induced fibrosis, imatinib
prevented the differentiation of fibroblasts into myofibroblasts
and reduced the synthesis and accumulation of proteins of the
extra-cellular matrix in the skin, significantly ameliorating the
mice phenotype (92, 93). Besides, imatinib was also effective
against pulmonary, renal and liver fibrosis. In the same model,
imatinib significantly prevented pulmonary fibrosis by inhibiting
proliferation of mesenchymal cells (93).
In one preclinical study, Belle et al. used a murine model of
Scl-cGvHD to assess the therapeutic impact of imatinib;
published data indicated that imatinib is able to reduce the
proliferation of both total T cells and T-regs in the spleen.
Nevertheless, despite the inhibition of PDGFR, there was noTABLE 3 | Translation of selected tyrosine kinase inhibition strategies from animal models of cGvHD into clinical trials.
Tyrosine
kinase
inhibitor
Main conclusion from the preclinical
model of GvHD (year)
Reference Main conclusion from the clinical trials (year) Reference
Ibrutinib Inhibition of Btk and Itk with ibrutinib Is
Effective in the Prevention and treatment of
cGvHD in Mice.
(39, 53,
73)
Both Btk and Itk may be required for the development of cGvHD
and inhibition of these signaling molecules by ibrutinib may prevent
or even treat cGvHD
(62)
Fostamatinib Fostamatinib is effective in treating
established cGvHD in mice
(38, 43) Ongoing
Fostamatinib—preventing and treating cGvHD after allogeneic
stem cell transplant
ClinicalTrial.gov identifier
NCT02611063
(43)
Entospletinib
(ENTO)
Inhibition of Syk with entospletinib prevents
ocular and skin GVHD in mice
(74) Ongoing
Entospletinib—preventing and treating cGvHD after allogeneic
stem cell transplant
ClinicalTrial.gov identifier
NCT02701634
Ruxolitinib Ruxolitinib improves the severity cGvHD
significantly
(75) Ruxolitinib may prevent or even treat SR-cGvHD (76)
Imatinib Impact Unclear. In one study, imatinib had
limited impact on Scl-cGvHD, while in
another, it prevented it
(77, 78) Imatinib may prevent or even treat SR-cGvHD (79, 80, 81)
Nilotinib Nilotinib prevents and treats Scl-cGvHD (95, 96,
78)
Nilotinib may prevent or even treat patients with SR- or steroid-
dependent cGvHD
ClinicalTrial.gov
identifier:
NCT01810718,
NCT01155817
(84)
Ixazomib Ixazomib may prevent GVHD
Unknown for cGvHD
(85) Combination of ixazomib and cyclosporine A may be able to
prevent cGvHD
(50)
Baricitinib Baricitinib prevents and/or reverses
established GvHD.
Unknown for cGvHD
(86) Baricitinib may prevent or even treat cGvHD ClinicalTrial.gov identifier
NCT02759731
Vismodegib Unknown N/A Vismodegib may treat SR-cGvHD ClinicalTrials.gov
identifier: NCT02337517
(87)
Sonidegib
(LDE225)
Sonidegib prevents and treats Scl-cGvHD (88) Sonidegib may treat SR-cGvHD ClinicalTrials.gov
identifier:
NCT02086513
(89)October 2020 | VoaGvHD, acute graft versus host disease; cGvHD, chronic GvHD; TKI, tyrosine kinase inhibitor; Btk, Bruton tyrosine kinase; TKI, tyrosine kinase inhibitor; Itk, Interleukin-2-inducible kinase;
Syk, spleen tyrosine kinase; Scl-cGvHD, Sclerodermatous cGvHD; SR-cGvHD, steroid-refractory cGvHD; N/A, not applicable.lume 11 | Article 578314
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(77). The impact of imatinib on liver fibrosis is more debated:
indeed, it significantly decreased the expression of some fibrosis
markers, such as a-SMA, Pcol1A1, and Hsp47 (94), but reduced
only the early liver fibrogenesis without preventing the long-term
fibrosis progression (95). Moreover, in a small series of CML
patients, our group recently showed that imatinib is able to
reduce the expression of several genes that usually are highly
expressed in autoimmune diseases. Genes such as ANX4A,
which is highly expressed in the Sjogren’s syndrome, CASP10,
highly expressed in Crohn’s disease, CEACAM8 and CTSG,
overexpressed in arthritis, ITGAM, elevated in psoriasis, and
PGLYRP1, whose high levels have been documented in chronic
gingivitis, were all reduced by imatinib; thus, supporting the
“anti-inflammatory” power of this drug (96).
In 2002, it was reported for the first time that in a series of 23
CML patients with bone marrow fibrosis, treatment with
imatinib for 3 months induced a marked regression of bone
marrow fibrosis (97). Two years later, another group
demonstrated that imatinib reduced fibrosis by at least 2
grades in 61% and by at least 1 grade in 85% of cases,
independently on the cytogenetic response (98). Similar
successes were reported in patients with treatment-resistant
systemic sclerosis, where skin fibrosis generally was more
responsive than lung fibrosis. In this context, the authors
showed that imatinib decreased the phosphorylation both of
PDFGR and of c-ABL1 in the skin of systemic sclerosis (SSc)
patients (99). This finding is particularly interesting since SSc
may resemble Scl-cGvHD, which paves the way for a similar
imatinib treatment approach in Scl-cGvHD patients.
On this basis, in 2009, Olivieri et al. reported the efficacy of
imatinib at 200 mg/day in a series of 19 patients with refractory
cGvHD, where the organs mostly involved were skin, lungs and
bowel. After 6 months of treatment, half of the patients showed a
significant improvement of cGvHD signs, especially in skin
fibrosis (79). The same conclusions were drawn by Magro
et al. who reported that imatinib 400 mg/day was able to
reduce skin sclerosis within 2 months of treatment. They
investigated the safety and efficacy of imatinib in 14 patients
with Scl-GVHD: with a median follow-up of 11.6 months, ORR
was 50%, including 28% of CR and 71% of PR and a significant
reduction of steroid dose. Imatinib was well tolerated in most
patients but in 29% of them, adverse events (muscle cramps,
nausea diarrhea, and fatigue) led to treatment discontinuation
(100). In addition, there is some evidence to suggest that imatinib
can improve the severity of cGvHD and at the same time allow
for the withdrawal of systemic corticosteroids without further
deteriorating the disease symptoms (79, 80, 99, 101, 102).
A possible explication of these different results could be
probably found in some pharmacogenetic aspects. Imatinib is
substrate of transmembrane influx and efflux pumps, as clearly
showed in CML where the combination of polymorphisms of the
human organic cation transporter type 1 (hOCT1) influx pump
and of one of the most important efflux pumps (ATP-binding
cassette sub-family B member 1; ABCB1) seem to influence
either the plasma level or the drug intra-cellular concentrations,Frontiers in Immunology | www.frontiersin.org 9with a clear impact on toxicity and efficacy (103). Analogously,
the impact of transporters in the intake of imatinib by dermal
fibroblast has been recently assessed by a German group: OCT1,
OCT2, organic cation transporter novel type 1 (OCTN1),
OCTN2, and Multidrug and toxin extrusion 1 (MATE1) were
expressed in dermal fibroblasts and the expression and activity of
MATE1 were deemed responsible for imatinib uptake. On the
other hand, MATE1 expression seemed to be correlated to
cytokines, such as PDGF subunit B (PDGFB), and to the
NOTCH signaling pathway. Indeed, in dermal fibroblasts, the
NOTCH pathway is highly activated and blockade of this
signaling network normalized the transporter function of
MATE1 and increased the imatinib efficacy in fibroblasts from
patients with SSc (104).
Nilotinib is a second-generation FDA approved TKI that
could also be used as first-line treatment of CML. Like imatinib,
it targets BCR-ABL1 and PDGFR with a higher affinity and lower
IC50 compared with imatinib, so offering higher rates of early and
deep molecular responses—conditions necessary also for a
further interruption of treatment (105–108). In preclinical
cGvHD models, nilotinib has been able to prevent Scl-cGvHD
by targeting and inhibiting the aberrant activation of the pro-
fibrotic c-ABL1 kinase and PDGFR (82, 83).
In another murine model of liver fibrosis, nilotinib decreased
TNF-a, TGF-b, receptor for advance glycation endproducts
(RAGE), and high-mobility group box 1 protein (HMGB1)
mRNA expression, decreased nitric oxide levels and increased
glutathione peroxidase activity, with significant reduction of
fibrosis (83).
The anti-inflammatory and immunomodulatory effects of
nilotinib on cGvHD were further highlighted when cultured
CD3-positive peripheral blood mononuclear cells from healthy
donors were exposed to varying concentrations of this TKI.
Nilotinib suppressed the production of pro-inflammatory
cytokines, including IL-2, IL-10, IL-17, IFN-g and TNF-a;
nevertheless, it had little or no effect on the frequency of Tregs,
B and NK cells (109).
Elevated levels of TGF-b as mentioned earlier, has been
found in cGvHD patients though the mechanism through
which it contributes to the pathogenesis of the disease remains
elusive. In their study, Busilacchi et al. demonstrated that
nilotinib represses the growth of fibroblast isolated from
cGvHD patients and causes earlier senescence in these cultured
cells compared to normal fibroblasts. More importantly,
nilotinib treatment led to the downregulation of both COL1a1
and COL1a2, along with TGF-b inhibition, which was associated
with reduction of intracellular phospho-Smad2. Hence,
suggesting that TGF-b inhibition at intracellular and systemic
level denotes a crucial anti-fibrotic apparatus of nilotinib in a
clinical setting (31).
Recently, Olivieri et al, conducted a phase I/II study in which
they evaluated the safety and maximum tolerated dose (MTD)
of nilotinib in 22 SR-cGvHD patients with multiorgan
involvement. MTD could not be reached after dose increase of
up to 600 mg/day, and according to the 2005 and 2014 NIH and
GITMO [an exploratory approach, combining objectiveOctober 2020 | Volume 11 | Article 578314
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months were 27.8%, 22.2%, and 55.6%, respectively. Overall
survival (OS) at 48 months was 75%, whereas, the failure free
survival (FFS), according to the NIH and GITMO criteria was
30% and 25%, respectively. Adverse events that were attributed
to nilotinib treatment included itching, headache, nausea,
cramps, mild anemia, and asthenia. Nonetheless, it was
concluded that the safety profile of nilotinib and long-term
outcome makes this TKI an attractive option in SR-
cGvHD (110).
There are currently a number of ongoing phase I/II studies
that are aimed at evaluating the safety and efficacy of nilotinib in
patients with steroid-refractory or steroid-dependent cGvHD
(ClinicalTrials.gov identifiers: NCT01810718, NCT01155817).
Btk and Itk Inhibition
Ibrutinib is a first-generation TKI which in humans, targets and
impedes the activation of B and T cells signaling by binding to
and inhibiting Btk and Itk, respectively (31, 65). In a phase II
trial, ibrutinib offered to SR cases resulted in 67% of rapid
multiorgan responses (62). No major hemorrhages were
reported and atrial fibrillation was reported only in 2% of
cases. Overall, treatment discontinuation rate by 2 years of
treatment occurred in one-third of cases. Ibrutinib is approved
by the FDA for the treatment of SR-cGvHD, and recently, this
drug showed a significant improvement of quality of life in a
series of 42 patients affected by cGvHD (111).
Syk Inhibition
Fostamatinib, like ibrutinib, is a small molecule first-generation
TKI, but unlike ibrutinib, fostamatinib is able to ameliorate the
severity of cGvHD by targeting Syk and blocking its down-
stream signaling. It also prevents the production of chemokines
and pro-inflammatory cytokines that are involved in the
activation of CD4+ T cells and their subsequent differentiation
into a Th1 or Th17 phenotype (36, 38, 43). Using mouse
models of cGvHD with multiorgan system, Flynn et al.
identified Syk-mediated BCR signaling in murine allogeneic
B cells as a facilitator of cGvHD and they further validated
targeting and inhibiting Syk with fostamatinib as an effective
approach for the treatment of cGvHD (43). In a similar study,
using a murine model of Scl-cGvHD, Huu et al. observed Syk
activation and phosphorylation in B and T cells, as well as
macrophages after allo-HSCT, and Syk inhibition using R788
(fostamatinib sodium) significantly reduced the severity and
fibrosis of Scl-cGvHD. They further showed that R788 was not
only effective at inhibiting the production of IL-6 by
macrophages, but also production of IL-13, IL-17A, and
IFN-g by CD4+ T cells (38).
There is currently no reported clinical study highlighting the
effects of fostamatinib in cGvHD. However, based on results
from in vitro and in vivo preclinical data in cGvHD (38, 75),
fostamatinib is currently being evaluated for the treatment and
prevention of cGvHD in a phase I clinical trial. Enrolled patients
will receive fostamatinib 100 mg qd, 150 mg qd, or 100 mg bid
from day +90 days after transplant and up to 1 yearFrontiers in Immunology | www.frontiersin.org 10(ClinicalTrials.gov identifier: NCT02611063). Results of this
trial have not yet been presented.
Blockade of JAK1/2 Signaling
Preclinical and clinical data suggest that JAK1/2 signaling may
play an important role in the pathogenesis of B- and T cell-
mediated GvHD (75, 113). This notion is supported by the
requirement of a constant activation of cytokine receptors that
are necessary for the production of a number of key cytokines
which are implicated in the pathogenesis of GvHD by JAK1/2.
Ruxolitinib, a JAK1/2-inhibitor, has been used to suppress T
cell activation via inhibition of cytokine receptor-mediated
signaling. Inhibition of this pathway by ruxolitinib improves
the outcome of subjects affected by cGvHD not only in murine
models, but also in patients (75). JAK1/2 inhibition by
ruxolitinib and the resulting attenuation of several murine
cGvHD features, is possibly in part through the down-
regulation of IFN-g signaling (75). This drug has been reported
to be effective also against the BOs, characterized by fixed airway
obstruction and bronchiolar inflammation. In a series of five
pediatric patients, two had a partial response (PR), and one an
improvement in FEV1 rapidly after starting ruxolitinib (114). In
addition, a recent meta-analysis, which included eight different
studies that was focused on cGvHD, reported that ruxolitinib
offered 62% of overall responses, with 27% of complete and 45%
of partial resolution of GvHD signs and symptoms (115).
Itacitinib is a powerful anti JAK1 inhibitor that is effective in
treating connective tissue diseases (116). In a phase-1 study on
aGvHD, when administered at 200 or 300 mg, it induced 78.6%
and 66.7% of overall response rate, respectively, with 70.6% of
successes in steroid-refractory patients (117). On this basis, two
studies trying itacitinib in cGvHD recently started the accrual
(ClinicalTrials.gov identifier: NCT04200365, NCT03584516).
Proteasome Inhibitors
Bortezomib is a proteasome inhibitor, which in a phase II trial,
administered at 1.3 mg/m2 i.v. on days 1, 8, 15, and 22 of each 35-
day cycle for 3 cycles, was used in combination with prednisone
for initial therapy of cGvHD. This combination was well
tolerated, with limited occurrence of sensory peripheral
neuropathy. The ORR was 80%, with only 10% of CRs,
especially in skin (73%), gastrointestinal tract (75%), and liver
(53%). One-third of cases showed a significant improvement of
symptoms referred to joints, muscles, or fascia (118). More
recently, it has been reported that bortezomib is well tolerated
and effective in pulmonary cGvHD: in 17 patients, with a cGvHD
lasting from more than 3 years, bortezomib induced a significant
reduction of forced expiratory volume (FEV1) decline (from
-1.06%/month before to -0.25%/month after treatment) (119).
Ixazomib. Interesting data are coming from the murine
model where ixazomib, a second-generation proteasome
inhibitor, has been used: it suppressed naïve human dendritic
cells (DC) maturation, reducing their pro-inflammatory cytokine
production, with a final improved survival of mice (85).
Ixazomib was also able to induce apoptosis of activated
T lymphocytes, reduce effector CD4+ T cells in bone marrow
and spleen, increase Tregs in lymph nodes, Peyer patches andOctober 2020 | Volume 11 | Article 578314
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employed in relapsed multiple myeloma (120), for treating
cGvHD (50). When administered at 4 mg on days 1, 8, and 15
of a 28-day cycle for up to six total cycles, ixazomib showed 34%
of ORR at 6 months; overall survival (OS) at 6 and 12 months
was 92% and 90%, respectively. Interestingly, this therapy was
well tolerated, because no subjects discontinued the treatment by
12 months (121). Moreover, after ixazomib exposure, serum
BAFF levels decreased, so supporting a possible immune
modulatory role for this new drug (122).
Monoclonal Antibodies and Fusion
Proteins
Like the TKIs, the efficacy profiles along with the mechanism of
action of most of these mAbs and fusion proteins are known, as
most of them are currently employed in the clinic to treat
autoimmune diseases, such as rheumatoid arthritis (105).
These compounds have been used to target various immune
cells including B cells, T cells and macrophages in cGvHD
settings. Rituximab, obinutuzumab, and ofatumumab are all
anti-CD20 mAbs that have been shown to deplete B cells and
thereby prevent B-cell clonal expansion in vivo cGvHD settings
(106). The anti-CD52 mAb Alemtuzumab, which targets and
deplete B cells, T cells, dendritic cells (DCs), and natural killer
(NK) cells, is also promising for the treatment of cGvHD (107).
In addition, a number of studies have reported the use of fusion
proteins to treat cGvHD (108, 123). The use of some of these
mAbs, antibody-drug conjugates, and fusion proteins for the
treatment of cGvHD are discussed below.
Rituximab is a chimeric mAb that targets CD20, a cell-
surface marker specifically found on pre-B and mature B-
lymphocytes. Binding of rituximab to CD20 results in
destruction of the lymphocytes by several mechanisms,
including antibody-dependent cell-mediated cytotoxicity,
complement-dependent cytotoxicity and direct apoptosis (124,
125). It is usually employed at 375 mg/m2 weekly for four doses;
it represents the mAb that is most frequently employed in
cGvHD treatment (126–128), including Scl-cGvHD (129) in
addition to other types of cGvHD (37, 130, 131). Recently, it
has been reported that rituximab offered 41% of responses at 1
year, 69% at 2 years, and 77% at 3 years. Interestingly, 67% of
responsive subjects tapered steroids. The probability of being
alive and free from cGvHD was 36%, 55%, and 57% at 1, 2, and 3
years, respectively (132).
Finally, combining B cell depletion with rituximab (375 mg/m2,
once per week, for 4 weeks) followed by TKI inhibition with
nilotinib (200 mg, twice daily, for 6 months) have shown a more
profound and long-lasting response (8% CR, 63% PR) with a higher
survival rate (96.6% in 1 year) in patients with Scl-cGvHD (129).
Ofatumumab is another fully human anti-CD20 mAb, which,
like Rituximab, targets, and depletes B lymphocytes (133).
Administration of ofatumumab alone or in combination with
glucocorticoids has demonstrated clinical improvement of cGvHD
symptoms in different studies (134). In a small series, Ofatumumab
was administered at 1000 mg on days 1 and 14 without dose-
limiting toxicity. Fatigue, transaminitis, and infusional reactionsFrontiers in Immunology | www.frontiersin.org 11were observed, but there were no cases of hepatitis B reactivation or
progressive multifocal leukoencephalopathy. At 6 months, the ORR
was 72%, with 36% of complete responders (CRs) and 90% of
patients who reduced the steroid dose (135).
Obinutuzumab is a novel powerful humanized anti-CD20
mAb. A randomized study with this anti-CD20 antibody, infused
at 3, 6, 9, and 12 months from transplantation, is now opened to
enrollment (ClinicalTrials.gov identifier: NCT02867384).
Begelomab is a murine IgG2B mAb against CD26 that usually
favors T cell migration. In a series of 28 patients, begelomab
was administered at 2–4.5 mg/day for 5 days, with possible 6
additional doses in 3 weeks, and this cohort was compared with
82 matched controls who received anti-thymocyte globulin, ECP,
mycophenolate, sirolimus, etanercept, high dose cyclophosphamide.
Begelomab rendered a more effective result than conventional
treatments, with an ORR of 75% vs 41%, with particular
improvement in the gut (ORR 82% vs 34%). This translated into
an advantage in terms of outcome, with 1-year OS of 50% vs 31% of
the controls (136). In another recently published study, begelomab
was shown to induce responses in over 60% of SR-aGvHD patients,
including those with severe gut and liver GvHD, having failed one
or more lines of treatment. Begelomab was administered to 69
patients with SR-aGvHD; of which, 8, 33, and 28 had severity of
GvHD grades II, III, and IV, respectively. Notably, 28 of the 69
patients were from two prospective studies (EudraCT No. 2007-
005809-21; 2012-001353-19) and 41 on a compassionate use study;
the median age was 42 and 44, respectively. In both the prospective
and compassionate groups, day 28 responses to begelomab were 75%
and 61%, respectively, while the CRRs were 11% and 12%. Responses
for grade III GvHDwere recorded in 83% and 73% of patients, while
responses in grade IV GvHD were recorded in 66% and 56% of
patients in the two groups, respectively. Interestingly, non-relapse
mortality at 6 months was 28% and 38%; and in general, 64%, 56%,
68% responses for skin, liver, and gut stage III–IV GvHD,
respectively, were recorded. The 1-year OS was 50% for the
prospective studies and 33% for the compassionate use patients.
More importantly, of the 28 surviving patients, 12 developed
cGvHD, where the severity was mild in five, moderate in five, and
severe in two patients. In addition, no adverse events directly
attributable to begelomab were reported (30). Begelomab was
recently granted Orphan Drug Designations (ODD) by the FDA
for the treatment of SR-aGvHD in the USA, EU and Switzerland.
While the begelomab effect on aGvHD is an interesting and
encouraging finding, there is to date, no clinical trials investigating
the effect of begelomab in cGvHDpatients. Nonetheless, studies have
shown that CD26 may play a role in the development of pulmonary
cGvHD, and that treating human umbilical cord blood (HuCB-
NOG) transplant mice with the fusion protein caveolin-1-Ig (Cav-
Ig), prevents the development of pulmonary cGvHD in these mice
by binding to caveolin-1 on the surface of APCs and to CD26 on T
cells, thereby, blocking the interaction between CD26 and caveolin-1
(137). Whether begelomab can have a similar effect in pulmonary
cGvHD and/or other types of cGvHD remains an open question.
Infliximab is a chimeric monoclonal anti-TNF-a antibody,
which has been successfully employed for treating aGvHD (29,
138). For cGvHD, it has been reported that two infusions at 10 mg/October 2020 | Volume 11 | Article 578314
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pediatric patient (139). Another anti-TNF-a agent, which is a fusion
protein with promising signs of ameliorating cGvHD, is Etanercept.
Etanercept was administered to 21 patients with steroid-refractory
aGvHD (SR-aGvHD) and cGvHD at 25 mg twice weekly for 4
weeks, followed by 25 mg weekly for another month. Overall
response rate (ORR) was 52%, with higher efficacy in gastro-
intestinal aGvHD (140).
Alemtuzumab is an anti-CD52 mAb, which targets not only
lymphocytes including B cells, T cells and NKs, but also DCs
(141, 142). Alemtuzumab has already been employed for the
treatment of chronic lymphocytic leukemia (107). In 2008,
alemtuzumab was reported for the first time as an effective
agent in a patient with extensive cutaneous cGvHD, who was
already treated unsuccessfully with steroids, cyclosporine-A,
sirolimus, tacrolimus, mychophenolate mofetil, infliximab, and
rituximab. In this patient, all ulcers and pain were resolved by
month 7 of therapy with alemtuzumab, administered at 10 mg/
day subcutaneously for six consecutive days every 4 weeks (143).
Importantly, not only is alemtuzumab effective in treating
cGvHD, but is also able to prevent or lessen the incidence of
the disease (144, 145), all of which highlights the significance of
this agent in both prophylaxis and treatment of cGvHD.
Brentuximab Vedotin is an anti-CD30 antibody-drug
conjugate already employed in Hodgkin’s (146) and in cutaneous
lymphomas (147). When used to treat cGvHD, it offered 47% PRs,
with 65% of patients able to decrease the steroid dose.
Notwithstanding its good efficacy, the toxicity was judged too
high, with 41% of patients developing grade 3 or 4 adverse
events (in particular severe peripheral neuropathy), thus
sustaining the need of larger studies in cGvHDwith this drug (148).
Axatilimab (SNDX-6352) is a humanized IgG4 mAb that
binds to the colony-stimulating factor 1 receptor (CSF-1R) and
inhibits its function. CSF-1R is a receptor for the cytokine CSF-1,
which is responsible for the production, differentiation and
function of macrophages. By binding to CSF-1R and inhibiting
it, axatilimab may be able to disrupt the activities of donor-
derived pro-inflammatory macrophages that have been shown to
promote cGvHD in the lung and skin (149). Axatilimab is
currently being evaluated in a phase I study for its effects in
patients with active cGvHD (ClinicalTrials.gov identifier:
NCT03604692). Nevertheless, the role of anti-CSF-1R antibodies
in cGvHD treatment needs further studies, because it has been
reported that axatilimab is also able to reduce resident
macrophages, while having no effect on inflammatory monocyte
recruitment in models of aGvHD (149).
Alefacept is a full dimeric human leukocyte-function-associated
antigen (LFA)-3/IgG1 fusion protein used for treating psoriasis; a
disease which is now commonly classified as an autoimmune
disease. Alefacept inhibits the activation of T cells by interfering
with the CD2 receptor on T cells, and thus blocks T cell proliferation
(150–152). Alefacept was demonstrated to be effective for also
treating cGvHD, with eight out of 12 patients responding after 2
weeks of treatment. Unfortunately, this response was only
temporary, and infections, pericarditis and a squamous cell
carcinoma of the lip were observed (108).Frontiers in Immunology | www.frontiersin.org 12Abatacept, a soluble fusion protein comprising the
extracellular domain of human cytotoxic T-lymphocyte antigen
(CTLA)-4 linked to the Fc portion of IgG1 and interferes
with the CD28 signaling pathway of T cells by interfering with
CD80 and CD86 expressed by antigen-presenting cells (APC).
This compound is used for treating the autoimmune disease
rheumatoid arthritis, and also seems promising for the treatment
of Scl-cGvHD. When administered at 10 mg/kg, it has been
reported to be well-tolerated and to offer 44% of PRs and
reduction in prednisone usage to half of the responsive
patients (123).
Other Novel Strategies to Target cGvHD
Effector Cells
Other novel approaches to target cGvHD effector cells include:
Ⅰ Blocking cytokines, such as IL-17 and IL-22, which are
responsible for Th17-mediated cGvHD (153, 154), or using low
doses IL-2 to induce the expansion of Tregs, which will in turn
suppress Tfh cells (155). Tfh cells can promote cGvHD through
their support for B cells in GC development, allowing B cell
differentiation into plasma cells, leading to the deposition of allo-
antibodies into target organs (156).
The possibility of targeting ROCK2, which is able to bind
phospho-STAT3 to form a ROCK2/STAT3/JAK2 complex and
control the Th17 genesis, was recently reported (157). At the
2018 American society of hematology (ASH) meeting, it was
demonstrated that the new ROCK2 inhibitor KD025 is able to
reduce levels of IL-21 and IL-17 and to increase the number of
Tregs. In a small series of 17 patients who already received three
lines of therapy, KD025 induced within 2 months, 65% of
responses across all affected organ systems except lung; 82% of
them sustained for more than 20 weeks (158).
In addition, high levels of both IL-17 and IL-22 have been
reported in the skin of patients with cutaneous cGvHD, which
was also attributed to an IL-6-dependent increased secretion of
these cytokines by donor CD4+ T and IL-22+-Th cells (153). The
anti-IL-22 mAb could be a possible option for treating cGvHD,
as already demonstrated in murine models for aGvHD, where it
reduced TNFa and IFN-g levels, but at the same time, increased
Treg populations (159). Two clinical trials with the anti-IL-22
antibody in aGvHD are now in progress in the USA
(ClinicalTrials.gov identifier: NCT02406651, NCT03763318),
paving the way for a possible translation into a cGvHD setting.
ⅠⅠ Blocking CD40L and IL-21R to prevent Tfh and GC B cell
response (37, 160).
ⅠⅠⅠ Inhibition of the NAD-dependent protein deacetylase
sirtuin 1 (sirt1), which regulates different subsets of T cells and is
required not only for maintenance of T cell tolerance, but also for
promoting Th17 responses (161–164). The important role played by
this enzyme in B- and T cell interaction during the development of
GvHD was recently highlighted by Daenthanasanmak et al. (165).
In a murine model, the authors demonstrated that donor T cells
lacking sirt1 reduced B cell activation and differentiation but
increased Tregs. Moreover, administration of the sirt1 inhibitor
selisistat (EX 527) resulted in reduced Tfh responses along with
preventing and treating cGvHD by downregulation of IFN-g, IL-17,October 2020 | Volume 11 | Article 578314
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pathogenesis (165);
IV Inhibition of the Hedgehog (Hh) signaling pathway. This
pathway is involved in the regulation of cellular differentiation
during embryonic development (166) and in control of cell
proliferation and carcinogenesis (167). The role of Hh signaling
in cGvHD was investigated by Zerr et al. (88), where they clearly
demonstrated how the Hh pathway plays an important role in the
pathophysiology of cGvHD. Based on these preclinical results,
Vismodegib, a potent inhibitor of Hh, and already employed for
basal cell carcinoma, is currently being evaluated for the treatment
of cGvHD (ClinicalTrials.gov identifier: NCT02337517). It has
been reported in a very small series that Vismodegib at 150mg/day
induced partial responses in five out of eight patients; nevertheless,
half of them stopped treatment due to toxicity (dysgeusia, fatigue,
elevated lipase). The median time to response was 103 days and
the duration of response was 7.8 months (87). Another Hh
inhibitor, Sonidegib, offered 47% of partial response in skin in
a small series of 8 patients with Scl-cGvHD; unfortunately,
patients reported worsening of quality of life, especially in non-
responders (89).
V Inhibition of NOTCH signaling. In a murine model of
multi-organ cGvHD, it was recently reported that Delta-like
ligand 4 (Dll4)-driven NOTCH signaling is essential for the
development of cGvHD and that Ab-mediated (anti-Dll1/anti-
Dll4) blockade of this pathway prevented and treated cGvHD
(168). Indeed, the activation of NOTCH signaling induces an
increased production of pro-inflammatory cytokines, decreases
Tregs and increases pathogenic GC B cell population through
increase in Tfh cells, leading to an increased tissue damage and
collage deposition. Inhibition of NOTCH signaling on the other
hand, impedes the production of pro-inflammatory cytokines,
increases Tregs and inhibits GC formation, hence, preventing
target organ damage (168).
VI Inhibition of the mitogen activated extracellular signal
regulated kinases 1 and 2 (MEK1 and MEK2), which are
important components of the MAPK signaling pathway. In
murine models, the RAS/MEK/ERK pathway is activated in naive
but not in effector memory T cells (169). Consequently, the MEK
inhibitor Trametinib suppressed GvHD-inducing T cells while
sparing antitumor GVL and virus-specific T cells in murine
models characterized by skin sclerosis and alopecia (170).
Sclerosis and alopecia are both not cGvHD but are high
frequency cutaneous manifestations that often occur in cGvHD
(171, 172), which makes MEK inhibition relevant to cGvHD.
VII Inhibition of the PI3K signaling pathway. PI3Ks are a
family of kinases of different classes involved in several cellular
processes including metabolism, growth, differentiation, and
proliferation. PI3K delta (PI3Kd) is an isoform preferentially
expressed in leukocytes; it seems to control IL-17 production, and
its inhibition has been reported to decrease the symptoms of
cGvHD in murine models (173, 174). It was shown in a
bronchiolites obliterans cGvHD mouse model that PI3Kd activity
in donor T cells is required for the development of cGvHD. In the
same study, the authors were able to interestingly demonstrate
that the PI3Kd inhibitor, GS‐649443, was able to treat either BO orFrontiers in Immunology | www.frontiersin.org 13Scl-cGvHD by limiting IL-17 production (175). The possibility of
testing PI3Kd inhibitors as a therapeutic strategy for cGvHD is
sustained also by the observation that Idelalisib, which is also a
PI3K inhibitor, is already employed in relapsed follicular lymphoma
and chronic lymphocytic leukemia (176), where it was shown to not
increase the onset of cGvHD when administered to patients
relapsed after alloHSCT (177).
VIII Inhibition of Inositol Kinase B. Inositol triphosphate
kinase B (ITPKB) is an enzyme involved in the regulation of
calcium intracellular levels, which is fundamental for T cell
activation and differentiation. It has been reported that ITPKB
inhibition induces apoptosis of activated T cells, and can control
T cell–mediated autoimmunity (178). Recently, it was shown in
two murine models of cGvHD (Scl and OB) that the ITPKB
inhibitor GNF362, significantly improved skin and lung GvHD
scores either by reducing M2 macrophage infiltration, or by
decreasing the number of IFN-g and IL-22 producing CD4+ T
cells, without impairing the graft-versus-tumor effect (179).
There is however, to date, no clinical trials with ITPKB
inhibitors for the treatment of cGvHD.CONCLUDING REMARKS AND FUTURE
PERSPECTIVE
We have summarized the more recent advances regarding the
preclinical and clinical activities of some newer immunotherapy-
based strategies for SR-cGvHD treatment, that include monoclonal
anti-B and T cell antibodies, along with TKIs, JAK-, MEK-,
proteasome-, and PI3K-inhibitors. An algorithm showing possible
second and third-line treatment options for cGvHD is given in
Figure 3. All these new strategies seem to offer great opportunities
for preventing or reversing cGvHD, as they are aimed at repairing/
maintaining immune regulation by targeting B cell (responsible for
the production of self-reactive antibody complexes) or T cell
(responsible for pro-inflammatory and pro-fibrotic cytokine
production) signaling and by reducing inflammation, which is
fundamental in the pathogenesis of cGvHD (73). However, the
biggest drawback for some of these emerging therapies for cGvHD
is the available evidence for their tolerability and efficacies, which is
frequently from preclinical or clinical trials that are trivial and
often conflicting.
Imatinib, dasatinib, nilotinib, ibrutinib, ixazomib, bortezomib,
and mAbs (anti-CD20, -CD30, -CD52) are all today commonly
employed in the clinical routine for treating acute and chronic
leukemias, myeloma and lymphoma. Nevertheless, our knowledge
on their efficacies and toxicities in the context of cGvHD is still
quite incomplete and many questions remain unanswered;
including: What is the tolerability of each of these promising
approaches in the setting of cGvHD? What could be the less toxic
and, at the same time, the most effective compound? Are the
adverse events that are already observed in the treatment of
cancers the same when these drugs are employed in patients
already allo-transplanted and receiving many concomitant (also
immunosuppressive) drugs? Is there an increased risk of secondary
malignancies during these new treatments? Is it possible to designOctober 2020 | Volume 11 | Article 578314
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effective drug according to the organ-specific clinical features of
cGvHD? Unfortunately, the majority of these questions are still
unresolved and to date, the only FDA-approved drug for the
treatment of adult patients with SR-cGvHD is ibrutinib, which, as
mentioned above, seems to be effective and well tolerated (61).
Importantly however, some mAbs, TKIs, and JAK1/2 inhibitors
are now in their late stages of evaluation and some are even already
employed in the clinics for “compassionate use”.
Perhaps some additional aspects, such as the pharmacogenetic
aspects, could help us to design for each patient a “tailored”
therapy. For example, it would be incorrect to use imatinib in
patients without an effective influx pump or with a high efflux of
the drug; in these cases, a TKI such nilotinib, which is superior to
imatinib could be advantageous.
We did not summarize options for cGvHD treatment using
cell-based therapies, such as mesenchymal stroma cells,
regulatory T cells, exosomes, and others, which will be
addressed in an additional paper.
Profound knowledge gaps in fully understanding the
biology of cGvHD have until now mired the discovery and
implementation of effective therapeutic strategies. Nonetheless,
we are hopeful that murine models and clinical data, which are
already available, will soon be able to help clinicians to control or
eradicate cGvHD complications of HSCT, thus, ameliorating the
quality of life of transplanted patients.Frontiers in Immunology | www.frontiersin.org 14In this complex scenario, the COST ACTION 17138
“EUROGRAFT” project (see “gvhd.eu” website), in the context
of whom this review has been realized, will lead to an improved
understanding of the pathogenesis of cGvHD and its associated
comorbidities, and will help us to develop a coordinated
approach to therapy, via a strict international collaboration
among experts in this field.AUTHOR CONTRIBUTIONS
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